Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2389569 | 0.97 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL3414562 | 0.91 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL2390228 | 0.89 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL18040444 | 0.88 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL30411194 | 0.87 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2ADORA3ADORA2A | |
| SCHEMBL3412331 | 0.86 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL2391745 | 0.86 | NPC1 (0.77) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL2001406 | 0.86 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL2389430 | 0.85 | ADORA3 (0.59) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD | |
| SCHEMBL2002143 | 0.85 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2043630-B1 | 6, 9-DISUBSTITUTED PURINE DERIVATIVES FOR COSMETIC USE | INST OF EX BOTANY ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2016-09-07 | — | — | EP | disclosed |
| US-20130072505-A1 | 6,9-Disubstituted Purine Derivatives and Their Use for Treating Skin | SZUCOVA LUCIE (CZ) | 2013-03-21 | — | — | US | disclosed |
| US-20110224238-A1 | 6, 9-Disubstituted Purine Derivatives and Their Use for Treating Skin | SZUCOVA LUCIE | 2011-09-15 | — | — | US | disclosed |
| US-20100234401-A1 | 6,9-Disubstituted Purine Derivatives and Their Use For Treating Skin | SZUCOVA LUCIE | 2010-09-16 | — | — | US | disclosed |
| EP-2043630-A2 | 6, 9-DISUBSTITUTED PURINE DERIVATIVES AND THEIR USE FOR TREATING SKIN | Institute of Experimental Botany, Academy of Sciences of the Czech Republic (CZ) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008770-A2 | 6, 9-DISUBSTITUTED PURINE DERIVATIVES AND THEIR USE FOR TREATING SKIN | INSTITUTE OF EXPERIMENTAL BOTANY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2008-01-17 | — | — | WO | disclosed |
| US-20080009508-A1 | 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin | INSTITUTE OF EXPERIMENTAL BOTANY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234401-A1 | 6,9-Disubstituted Purine Derivatives and Their Use For Treating Skin | UNG, P2RY6, MPG | NPC1 3196/4885RAB9A 1395/4885SMN1; SMN2 3167/4885 |
| US-20110224238-A1 | 6, 9-Disubstituted Purine Derivatives and Their Use for Treating Skin | UNG, P2RY6, MPG | NPC1 3196/4885RAB9A 1395/4885SMN1; SMN2 3167/4885 |
| US-20130072505-A1 | 6,9-Disubstituted Purine Derivatives and Their Use for Treating Skin | UNG, P2RY6, MPG | NPC1 3196/4885RAB9A 1395/4885SMN1; SMN2 3167/4885 |
| US-20080009508-A1 | 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin | UNG, P2RY6, MPG | NPC1 3196/4885RAB9A 1395/4885SMN1; SMN2 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.